Low Prices for Oil Cure Low Prices for Oil
Source: Bob Moriarty��(4/27/16)
Veteran investor Bob Moriarty discusses one company that is poised to benefit from the volatililty in the oil markets. More >

Are We or Are We Not in a New Gold Bull Market?
Source: Jack Chan for The Gold Report��(4/26/16)
Technical analyst Jack Chan has examined the charts and says that if we are in a new bull market, prices in both gold and gold equities should begin to pull back and consolidate soon. More >

LiTHIUM X Is Not Alone—Profiling This Marketplace Darling and Others in the Sweet Spot
Source: Patrice Fusillo of The Gold Report��(4/25/16)
After several years of bear markets for miners, many mining equities have lept upward in the last few months. LiTHIUM X Energy ranks among the leaders of the pack, up many-fold. Barry Allan, vice chair of mining at Mackie Research, and Research Analyst Ryan Hanley put out a report in March for the PDAC convention, highlighting a number of promising mining companies. In this interview with The Gold Report, Allan and Hanley profile a handful of those companies, including LiTHIUM X. More >

Hold Reservoir Minerals After Takeout: Adrian Day
Source: Adrian Day��(4/24/16)
On Sunday, Reservoir Minerals announced it has agreed to be acquired by Nevsun Resources. Adrian Day shares his initial thoughts on the deal. More >

Madness in the Crimex Trading Pits. . .
Source: Michael Ballanger��(4/22/16)
Precious metals expert Michael Ballanger discusses effects of the Bank of Japan's actions on the U.S. dollar, silver and gold. More >

President Trump? President Clinton? Gold Up in Both Scenarios
Source: Gordon Holmes of The Gold Report��(4/21/16)
Donald Trump and Hillary Clinton may have very little in common, but Barry Allan, vice chair of mining for Mackie Research Capital, says if either moves into the White House, the U.S. dollar will fall and gold will rise. A higher gold price bodes well for gold equities, and in this interview with The Gold Report, Allan and his colleague Ryan Hanley share the names of some of their top picks for this environment.
More >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Source: George S. Mack of The Life Sciences Report ��(4/20/16)
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. More >

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
Source: Special to The Life Sciences Report��(4/20/16)
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
More >

All Hail the Mighty Silver Bugs…
Source: Michael Ballanger��(4/20/16)
Precious metals expert Michael Ballanger examines silver's recent moves upward. More >

Looming Zinc Supply Shortage Good News for Producers and Explorers: Stefan Ioannou
Source: Patrice Fusillo of The Gold Report��(4/18/16)
The outlook for zinc appears bullish, says Stefan Ioannou of Haywood Securities, spearheaded by mine closures, dwindling production and the dearth of replacement projects. This looming supply gap could mean increased zinc prices by the end of the year, explains Ioannou in this interview with The Gold Report, a prospect that would bode well for one of the few pure-play zinc producers, as well as for an Australian explorer that may be on the cusp of a world-class discovery. More >

Gold Trading Model and COT Data Are in Conflict
Source: Jack Chan��(4/18/16)
Technical Analyst Jack Chan says his trading model is indicating that the gold sector is on a new major buy signal, but the COT data is bearish, so he is waiting for the COT to return to bull market values. More >

COT Report for the Week Ended April 12: Commercial Signal Failure Looms?
Source: Michael Ballanger��(4/17/16)
Precious metals expert Michael Ballanger dissects Friday's COT report. More >

The Canadian Shield Could Host the Next Bonanza Discovery: Eric Lemieux
Source: Patrice Fusillo of The Gold Report��(4/14/16)
Gold supply is getting tighter, deposits of quality are getting rarer and the project development timeline is getting longer. Enter Canada. The Canadian Shield still offers the possibility of break-out discoveries, says PearTree Securities analyst Eric Lemieux. The recent spate of M&A activity points to the potential of the region, and Lemieux discusses several companies that are well positioned to add value. More >

Deutsche Bank Silver Settlement: GATA Vindicated
Source: Michael Ballanger��(4/14/16)
Precious metals expert Michael Ballanger riffs on the news that Deutsche Bank is settling U.S. silver pricing litigation. More >

Drug Pricing, Presidential Politics, and Three Biotechs with Promise
Source: George S. Mack of The Life Sciences Report��(4/13/16)
While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk. In this interview with The Life Sciences Report, George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. More >

How Altius Minerals Is Taking Advantage of Market Weakness
Source: Adrian Day��(4/11/16)
Despite the bear market in resources, Altius Minerals has continued to make progress, according to Adrian Day of Adrian Day Asset Management. Day explains why the company remains one of his firm's top core holdings, and why more opportunities lie ahead. More >

Long and Intermediate Trends Crushing Commercials…
Source: Michael Ballanger��(4/8/16)
Precious metals expert Michael Ballanger discusses the tug-of-war going on between the Japanese yen and the U.S. dollar/Chinese yuan, and its effect on precious metals. More >

How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading
Source: George Mack of The Life Sciences Report��(4/6/16)
Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. For instance, Genentech's Herceptin (trastuzumab) is a blockbuster, bringing in $7.4B in revenue during 2015, but at one point investigators thought it was a complete failure. It took patience, time, additional capital and careful analysis of subpopulations of breast cancer patients to figure out that Herceptin would ultimately save many lives. In this interview with The Life Sciences Report, George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble.
More >

Jack Chan Sees New Major Buy Signal for Gold But Is Patient
Source: Jack Chan for The Gold Report��(4/6/16)
Technical analyst Jack Chan has examined the charts and says the gold sector is on a new major buy signal, which could signal a new bull market. But he is patiently waiting for confirmation. More >

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Source: Staff of The Life Sciences Report��(4/5/16)
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture. In this interview with The Life Sciences Report, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. More >

BonTerra Resources Delivers Its Own March Madness
Source: Thibaut Lepouttre of Caesars Report exclusively for Streetwise Reports��(4/4/16)
BonTerra Resources stock is up just over 70% in March and 146% in 2016. In March, BonTerra acquired nearly 1 Moz of gold at the Larder project and released great drill results on the Gladiator project, and there is more to come. Caesar's Report's Thibaut Lepouttre discusses the merits and effects of such a busy month. More >

Epic Battle Rages on: 'Ali-Frazier' in the Crimex Pits. . .
Source: Michael Ballanger��(4/1/16)
The battle raging between the Bullion Banks and Gold Speculators is every bit as spectacular as the Ali-Frazier fights of the 1970s, says precious metals expert Michael Ballanger. More >

The Gold-to-Silver Ratio: A Truly Generational Opportunity
Source: Michael Ballanger��(3/31/16)
Precious metals expert Michael Ballanger says that owning silver versus owning gold is a high-probability trade that could be the 2016 Trade of the Year.

More >

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
Source: George S. Mack of The Life Sciences Report��(3/30/16)
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. finds itself, says CEO David Kalergis. In this interview with The Life Sciences Report, Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. More >

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report��(3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >